Dimerix (ASX:DXB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Dimerix (ASX:DXB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
2026 AGM Notice of Meeting, Letter of Access and Proxy Form
Dimerix Announces Board Chair Transition
DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
Dimerix reports first 100 patients complete two-year ACTION3 treatment period
Dimerix at Canaccord Drug & Device and Ignite Conferences
First Patient Reaches Four Years in DMX-200 Clinical Program
First patient completes four years in Dimerix DMX-200 FSGS program as 93% of eligible patients enter extension study
Notification regarding unquoted securities - DXB
Notification of 2026 Annual General Meeting Date
Dimerix Presents at ASX SMIDcaps Conference 2026
Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
Dimerix draws down A$17 million to fund kidney disease trials
Waiver of Listing Rule 10.1 Granted
Dimerix Presents at E&P Healthcare Conference 2026
Dimerix DMX-652 Granted Mexican Composition of Matter Patent
Dimerix secures Mexican patent protection for DMX-652 through 2041
Dimerix Investor Presentation
Dimerix Secures A$34 Million Non-Dilutive Funding Facility
Trading Halt
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Dimerix reports $29.8 million loss, completes ACTION3 adult recruitment, expands global licensing with Everest Medicines
Dimerix Receives US$10M Upfront Payment from Everest
Dimerix receives US$10 million upfront from Everest Medicines for DMX-200 licensing in Asia
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
Dimerix Assumes U.S. IND Sponsorship for Phase 2 AKI Asset DMX-652
Dimerix Presents at Bioshares Summit 2026
Dimerix CEO Presents Diversification Strategy and Pipeline Progress at Bioshares Summit
Dimerix Quarterly Activities Report and Appendix 4C
Dimerix secures fifth licensing deal, expands pipeline with DMX-652 acquisition, and maintains strong funding through Phase 3 trial
Dimerix to Present at TechKnow Invest Conference 2026
US Patent Granted for Dimerix New Asset DMX-652
Dimerix secures US patent for DMX-652 with Phase 2 trial preparations underway for acute kidney injury
